Key result
Anti-Xa assays lack large randomized controlled trials correlating them with clinical outcomes, leaving the optimal method for monitoring intravenous unfractionated heparin therapy unknown.
Why the study?
Although some suggest anti-Xa assays should be preferred for monitoring intravenous unfractionated heparin, the best monitoring method is unknown due to a lack of large randomized controlled trials correlating assays with clinical outcomes.
What is the role of anti-Xa assays in monitoring intravenous unfractionated heparin therapy?
What is the role of anti-Xa assays in monitoring intravenous unfractionated heparin therapy?
This review highlights the clinical applications of anti-Xa assays for heparin monitoring while noting the absence of large randomized controlled trials to definitively establish the best monitoring method.
Anti-Xa monitoring for IV heparin should not yet supplant aPTT in practice; leaves open the optimal strategy pending outcome RCTs.
Although some suggest anti-Xa assays should be the preferred method for monitoring intravenous unfractionated heparin therapy, which method is best is unknown owing to the lack of large randomized controlled trials correlating different assays with clinical outcomes. This article provides an overview of heparin monitoring and the pros, cons, and clinical applications of anti-Xa assays.
No takes yet. Share an insight, caveat, or question.
Hutt et al. (2019) studied this question. Anti-Xa assays lack large randomized controlled trials correlating them with clinical outcomes, leaving the optimal method for monitoring intravenous unfractionated heparin therapy unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: